Clinical trial
Evaluation of the Reliability of Effect of Rimegepant for the Acute Treatment of Migraine Across Multiple Attacks
NCT06412965 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Evaluation of the Reliability of Effect of Rimegepant for the Acute Treatment of Migraine Across Multiple Attacks
- Lead sponsor
- Pfizer
- Phase
- Observational
- Overall status
- Completed
- Start date
- January 2, 2024
- Completion date
- January 3, 2024
- Enrollment
- 528 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.